Printer Friendly

ENVIRONMENTAL DIAGNOSTICS, INC. AND BOEHRINGER MANNHEIM CORPORATION ENTER INTO OPTION AGREEMENT

 ENVIRONMENTAL DIAGNOSTICS, INC. AND BOEHRINGER MANNHEIM CORPORATION
 ENTER INTO OPTION AGREEMENT
 BURLINGTON, N.C., Sept. 9 /PRNewswire/ -- Environmental Diagnostics, Inc. (OTC Bulletin Board: EDIT) reported today that it has entered into an Option Agreement with Boehringer Mannheim Corporation ("BMC") for certain patents and/or patent applications and other intellectual property possessed by the Company.
 Under the terms of the Option Agreement, Environmental Diagnostics and BMC agree to conduct negotiations relative to certain patents and related patents stemming from U.S. patent application Serial No. 338,123 filed Jan. 8, 1982. On Tuesday, Aug. 25, 1992, the U.S. Patent and Trademark Office (PTO) issued to EDI patent no. 5,141,875 (entitled Rotary Fluid Manipulator) which covers, among other things, a methodology for the performance of one-step assays -- one of the fastest growing and most important segments of the human/clinical diagnostic market. During the period of this Option Agreement, EDI agrees not to pursue negotiations with any other person or entity relative to the acquisition of licensing of these intellectual properties. BMC has paid to EDI a $50,000 non-refundable fee as compensation for the "stand-off period." The Option Agreement does not bind either BMC or EDI to enter into a definitive agreement.
 James D. Skinner, President and C.E.O. of EDI, stated, "BMC is one of the world's largest diagnostic companies with which EDI has a long and valued relationship. For the past year, EDI has been an OEM supplier to BMC. Although there is no obligation on either party to enter into a definitive agreement, both EDI and BMC are conducting discussions in a positive and cooperative fashion."
 Environmental Diagnostics, Inc. is an emerging, biodiagnostic company with patented technology for the performance of rapid, on-site assays including one-step assays. The Company currently has products on market or research and development and supply agreements that address the human/clinical, drugs of abuse, U.S. Department of Defense tests for biological substances, veterinary and agridiagnostic and of food safety testing markets.
 -0- 9/9/92
 /CONTACT: Peter Heath, Vice President-Finance and Chief Financial Officer, Environmental Diagnostics, 919-226-6311/
 (EDIT) CO: Environmental Diagnostics, Inc.; Boehringer Mannheim Corporation ST: North Carolina IN: MTC SU: JVN


CM -- CH007 -- 7401 09/09/92 10:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1992
Words:373
Previous Article:IRT PROPERTY SELLS SHOPPING CENTER PROPERTIES TO INGLES MARKETS
Next Article:CHRYSLER PRODUCES 3-MILLIONTH AIR-BAG-EQUIPPED VEHICLE, REPORTS FIRST CUSTOMER DUAL AIR-BAG DEPLOYMENT
Topics:


Related Articles
RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.
BOEHRINGER MANNHEIM AND GENSIA ANNOUNCE COLLABORATION
ENDOGEN, INC. NAMES DENNIS WALCZEWSKI VICE PRESIDENT OF SALES
GENZYME TRANSGENICS ANNOUNCES AGREEMENT WITH BOEHRINGER MANNHEIM
IGEN AND BOEHRINGER MANNHEIM COLLABORATION RESULTS IN NEW SERIES OF DIAGNOSTIC SYSTEMS
IGEN Announces Completion of Assay Development Milestones Under Supplemental Contract With Boehringer Mannheim
Corange/Boehringer Mannheim and Ontogeny Sign Collaborative Agreement to Develop Therapeutics in Bone Applications
IGEN Files A Complaint Against Boehringer Mannheim
Premier Announces Corporate Partnerships With Bayer Health Care Partners, Boehringer Mannheim Corporation, and 3M Health Care
Premier Adds Boehringer Mannheim Corporation to Corporate Partner Program

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters